Rapport Therapeutics, Inc. (RAPP) Form 424B5 — Oct 30, 2026
Rapport Therapeutics priced $150.0 million of 2.25% Convertible Senior Notes due 2032, with an initial conversion price of approximately $26.7750 per share versus a last reported sale price of $27.54. Net proceeds to the company are estimated at approximately $145.0 million after a 3.00% underwriting discount. Concurrently, the company is offering 8,333,334 shares at $21.00 per share plus 1,190,476 pre-funded warrants at $20.999, alongside a 1,428,571-share private placement at $21.00, for combined estimated net proceeds of approximately $215.7 million.
Key figures
- Debt Amount
- 150000000
- Interest Rate
- 2.25
- Maturity Date
- 2032-12-01
- Gross Proceeds
- $145.0 million net (notes offering; $166.8M with over-allotment); $215.7M net from concurrent equity offering + private placement ($243.9M with full over-allotment)
- Offering Price
- 21
- Shares Offered
- 8333334
- Runway
- through end of 2029
- Conversion rate
- 37.3483 shares per $1,000
- Cash june30 2026
- $436,077 thousand
- Conversion price
- $26.7750 per share
- Pre funded warrants
- 1,190,476 shares at $20.999
- Over allotment notes
- $22,500,000 principal
- Underwriting discount
- 3.00% ($4,500,000)
- Last reported sale price
- $27.54 (Oct 27, 2026)
- Private placement shares
- 1428571
- Shares outstanding june30 2026
- 47955079
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.